Q3 2026: the biggest rise of the cycle
ChemAnalyst’s quarterly averages show aspirin up in all three regions in Q3 2026:
- USA, CFR Los Angeles: USD 3,196.67/MT, up 13.63%
- Germany, CFR Hamburg: USD 3,078.33/MT, up 10.47%
- China, FOB Shanghai: USD 2,886.67/MT, up 9.34%
This is the fourth straight quarterly rise in each region, and the gains have sped up. The US index went from +0.79% in Q4 2025 to +2.53%, then +6.38%, then +13.63%. China went from +0.26% to +3.51%, then +4.24%, then +9.34%. Germany rose 5.30% in Q1 and 5.01% in Q2 before jumping 10.47% in Q3. Since Q4 2025, prices are up about 23.9%* in the US, 22.2%* in Germany and 18.0%* in China.
Book a free demo: https://www.chemanalyst.com/ChemAnalyst/PricingForm?Product=Aspirin
Why China moved: salicylic acid and inspections
In China, higher salicylic acid prices from July to September passed almost directly into aspirin conversion costs, lifting FOB offers each month. Phenol and acetic acid prices also rose, adding to costs. Environmental wastewater inspections idled salicylic acid units from time to time, which tightened raw material supply. Coal-power rationing and higher electricity tariffs raised variable costs and pushed marginal producers up the cost curve.
Export demand also strengthened. Buyers in the US, Brazil and Germany restocked ahead of Q4 tablet production. Producers put export margins ahead of volume and front-loaded shipments, which narrowed their discount against Indian offers. In India, firmer Chinese export offers reduced the import-parity discount, and steady domestic plants passed on higher feedstock costs.
Why the US rose most: freight and allocations
US prices are landed prices, so freight costs show up in them directly. Container rates from Shanghai to Los Angeles rose sharply, adding a large freight cost to West Coast CFR shipments. Chinese and Indian exporters cut spot allocations to the US and sent cargoes to higher-priced orders, reducing US availability in September. US buyers also bought their Q4 cold-and-flu requirements early. Warehouse stocks were adequate overall, but tighter allocations at origin left buyers less room to restock quickly.
The result is a wider gap over origin. The premium of LA over FOB Shanghai grew from about USD 133/MT* in Q4 2025 to USD 112/MT* in Q1, USD 173/MT* in Q2 and USD 310/MT* in Q3.
Germany: dearer imports, slower barges
Germany depends on imports, so its supply stayed ample but became more expensive. Higher salicylic acid costs widened raw material spreads. Freight from Shanghai to Hamburg rose sharply. Port waits and low water on the Rhine limited barge deliveries. Seasonal buying for winter OTC and cardiovascular programs gave sellers some extra pricing power in September. The Hamburg premium over Shanghai widened from about USD 73/MT* in Q4 2025 to USD 192/MT* in Q3. No plant shutdowns were reported.
Outlook: a likely October peak
ChemAnalyst’s three regional forecasts point to the same timing:
- China: firmness in October from seasonal buying, then a correction in November as buyers draw down inventories.
- Europe: a mild correction after October as European restocking ends and softer Chinese FOB prices pass through.
- USA: modest further gains into October, then softening later in Q4 as the season normalizes and inventories build.
For buyers who covered Q4 early, the peak may already be close. For those still to buy, timing within the quarter matters more than usual.
Track aspirin weekly with ChemAnalyst
ChemAnalyst tracks weekly prices for 1,000+ commodities, explains why prices moved, and publishes forecasts. Its analysts track plant shutdowns and 50+ ports from offices in Houston, Cologne and New Delhi.
Book a free demo: https://www.chemanalyst.com/ChemAnalyst/PricingForm?Product=Aspirin
Comments